Glycyrrhetinic acid mitigates radiation-induced pulmonary fibrosis via inhibiting the secretion of TGF-β1 by Treg cells

Jinmei Chen,Caihong Wang,Xiaoxian Pan,Yuping Zhan,Weitong Zhou,Shaoli Peng,Chun Chen,Mingwei Zhang,Ruilong Lan,Jiandong Wu,Fei Huang,Jinsheng Hong
DOI: https://doi.org/10.1016/j.ijrobp.2023.08.005
2023-08-16
Abstract:Purpose Radiation-induced pulmonary fibrosis (RIPF) is a common side effect of radiotherapy for thoracic tumors without effective prevention and treatment methods at present. The aim of this study was to explore whether glycyrrhetinic acid (GA) has a protective effect on RIPF and the underlying mechanism. Methods and Materials A RIPF mouse model administered GA was used to determine the effect of GA on RIPF. The cocultivation of Treg cells with MLE-12 cells or mouse embryonic fibroblasts and intervention with GA or Transforming growth factor-β1 (TGF-β1) inhibitor to block TGF-β1 were conducted to study the mechanism by which GA alleviates RIPF. Furthermore, injection of Treg cells into GA-treated RIPF mice to upregulate TGF-β1 levels was performed to verify the roles of TGF-β1 and Treg cells. Results GA intervention improved the damage to lung tissue structure and collagen deposition and inhibited Treg cell infiltration, TGF-β1 levels, epithelial mesenchymal transition (EMT) and myofibroblast (MFB) transformation in mice after irradiation. Treg cell-induced EMT and MFB transformation in vitro were prevented by GA, as well as a TGF-β1 inhibitor, by decreasing TGF-β1. Furthermore, reinfusion of Treg cells upregulated TGF-β1 levels and exacerbated RIPF in GA-treated RIPF mice. Conclusions GA can improve RIPF in mice, and the corresponding mechanisms are maybe related to the inhibition of TGF-β1-induced EMT and MFB transformation by Treg cells. Therefore, GA may be a promising therapeutic candidate for the clinical treatment of RIPF.
oncology,radiology, nuclear medicine & medical imaging
What problem does this paper attempt to address?